The latest progress of breast cancer treatment at 2023 ESMO

doi:10.19401/j.cnki.1007-3639.2023.11.002

Abstract

Abstract:

At 2023 Annual Meeting of European Society of Medical Oncology (ESMO), Several latest research achievements in the field of breast cancer were announced. For early-stage breast cancer, immune checkpoint inhibitor has not only continued to prove their value in the neoadjuvant treatment of triple-negative breast cancer (KEYNOTE-522 and NeoTRIP), but also shown their potential benefit in the neoadjuvant therapy of hormone receptor+/human epidermal growth factor receptor 2 (HER2)- breast cancer (KEYNOTE-756 and CheckMate 7FL). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (as shown in the MONARCHE and NATALEE studies) have also solidified an important position in the adjuvant intensive treatment of hormone receptor+/HER2- breast cancer. In advanced breast cancer treatment, new endocrine therapy options and antibody-drug conjugate (T-DXd and Dato-DXd) have opened up new therapeutic opportunities for hormone receptor+/HER2- patients. Pooled analyses suggest that T-DXd has demonstrated outstanding efficacy in brain metastases of HER2+ breast cancer. Dato-DXd in combination with immunization and the new targeted antibody-drug conjugate HS-20089 produced promising efficacy in first-line treatment of and post-line triple-negative breast cancer, respectively.

Key words: Breast cancer treatment, Immune checkpoint inhibitor, Cyclin-dependent kinase 4/6 inhibitors, Antibody-drug conjugate

CLC Number:

R737.9

ZHOU Teng, ZHANG Jian. The latest progress of breast cancer treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 981-988.

References 26

[1]	CARDOSO F. LBA21 KEYNOTE-756: phase Ⅲ study of neoadjuvant pembrolizumab (pembro) or placebo (pbo)+chemotherapy (chemo), followed by adjuvant pembro or pbo+endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer[J]. Ann Oncol, 2023, 34: S1260-S1261. doi: 10.1016/j.annonc.2023.10.011
[2]	LOI S, CURIGLIANO G, SALGADO R F, et al. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET)±NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC)[J]. Ann Oncol, 2023, 34: S1259-S1260. doi: 10.1016/j.annonc.2023.10.010
[3]	O’SHAUGHNESSY J, JOHNSTON S R D, HARBECK N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high-risk early breast cancer[C]. 2020 San Antonio Breast Cancer Symposium, 2020: Abstract GS1- 01.
[4]	JOHNSTON S, TOI M, O’SHAUGHNESSY J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes[C]. SABCS, 2022.
[5]	HARBECK N. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes[J]. Ann Oncol, 2023, 34: S1256. doi: 10.1016/j.annonc.2023.10.007
[6]	SLAMON D J, STROYAKOVSKIY D, YARDLEY D A, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase Ⅲ NATALEE trial[J]. J Clin Oncol, 2023, 41(17_suppl): LBA500. doi: 10.1200/JCO.2023.41.17_suppl.LBA500
[7]	BARDIA A, HORTOBAGYI G N, LIPATOV O, et al. LBA23 Invasive disease-free survival (iDFS) across key subgroups from the phase Ⅲ NATALEE study of ribociclib (RIB)+a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)[J]. Ann Oncol, 2023, 34: S1261-S1262.
[8]	KOI Y, TAJIRI W, KAWASAKI J, et al. The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer[J]. Ann Oncol, 2023, 34: S278-S324.
[9]	SCHMID P, CORTÉS J, DENT R A, et al. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase Ⅲ KEYNOTE-522 study[J]. Ann Oncol, 2023, 34: S1257. doi: 10.1016/j.annonc.2023.10.008
[10]	GIANNI L, HUANG C S, EGLE D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022: S0923- 7534(22)00113-2.
[11]	GIANNI L. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2023, 34: S1258-S1259. doi: 10.1016/j.annonc.2023.10.009
[12]	MITTENDORF E A, ZHANG H, BARRIOS C H, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100. doi: 10.1016/S0140-6736(20)31953-X pmid: 32966830
[13]	ROBERTSON J. Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)[J]. Ann Oncol, 2023, 34: S339-S340. doi: 10.1016/j.annonc.2023.09.561
[14]	TARANTINO P, HAMILTON E, TOLANEY S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962. doi: 10.1200/JCO.19.02488 pmid: 32330069
[15]	MODI S, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. doi: 10.1056/NEJMoa2203690
[16]	MODI S. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): updated survival results of the randomized, phase Ⅲ DESTINY-Breast04 study[J]. Ann Oncol, 2023, 34: S334-S335. doi: 10.1016/j.annonc.2023.09.553
[17]	BARDIA A. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): primary results from the randomised phase Ⅲ TROPION-Breast01 trial[J]. Ann Oncol, 2023, 34: S1264-S1265. doi: 10.1016/j.annonc.2023.10.015
[18]	OUYANG Q, YIN Y, SONG L, et al. SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC): results from a phase Ⅰ/Ⅱ, single-arm, basket trial[J]. Ann Oncol, 2023, 34: S337.
[19]	CURIGLIANO G, CASTELO-BRANCO L, GENNARI A, et al. ESMO metastatic breast cancer living guidelines, v1.1 May 2023[J]. Ann Oncol, 2021, 32(12): 1475-1495. doi: 10.1016/j.annonc.2021.09.019
[20]	MÜLLER V, BARTSCH R, LIN N U, et al. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review[J]. Cancer Treat Rev, 2023, 115: 102527. doi: 10.1016/j.ctrv.2023.102527
[21]	HURVITZ S A. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01, -02, and-03[J]. Ann Oncol, 2023, 34: S335-S336. doi: 10.1016/j.annonc.2023.09.554
[22]	AFTIMOS P G, TURNER N, O’SHAUGHNESSY J, et al. Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase Ⅲ TULIP trial[J]. Ann Oncol, 2023, 34: S340-S341.
[23]	ZHANG J. A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors[J]. Ann Oncol, 2023, 34: S340.
[24]	FUENTES-ANTRÁS J, GENTA S, VIJENTHIRA A, et al. Antibody-drug conjugates: in search of partners of choice[J]. Trends Cancer, 2023, 9(4): 339-354. doi: 10.1016/j.trecan.2023.01.003
[25]	SCHMID P. Datopotamab deruxtecan (Dato-DXd)+durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ⅰb/Ⅱ study[J]. Ann Oncol, 2023, 34: S337.
[26]	WU J, ZHANG J, LI H, et al. First-in-human/phase Ⅰ trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors[J]. Ann Oncol, 2023, 34: S336.